- Conditions
- Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Bone Sarcoma, Translocation-associated Soft Tissue Sarcoma, Synovial Sarcomas, Osteosarcoma Metastatic, Ewing Sarcoma, Ewing Sarcoma Metastatic, Sarcoma Metastatic, Sarcoma of Bone
- Interventions
- Biospecimen Collection, Computed Tomography, Echocardiography, Multigated Acquisition Scan, Zanzalintinib
- Procedure · Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2033
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 1,369
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Fluciclovine F18, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography, PSMA PET Scan, Relugolix, Stereotactic Body Radiation Therapy
- Procedure · Other · Drug + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2034
- U.S. locations
- 242
- States / cities
- Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 192 more
- Conditions
- COVID-19 Infection, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Electronic Health Record Review
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Juvenile Myoclonic Epilepsy
- Interventions
- Blood draw, Existing samples
- Other
- Lead sponsor
- King's College London
- Other
- Eligibility
- 10 Years to 40 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2026
- U.S. locations
- 3
- States / cities
- New York, New York • Columbus, Ohio
- Conditions
- Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test, Multigated Acquisition Scan, Selumetinib, Trastuzumab Deruxtecan
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Myc Inhibitor OMO-103
- Procedure · Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Allogeneic Hematopoietic Stem Cell
- Interventions
- fecal microbiota transplantation (FMT), No fecal microbiota transplantation (FMT), routine management
- Biological · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
- Interventions
- Biospecimen Collection, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Stereotactic Radiosurgery
- Procedure · Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Duarte, California • La Jolla, California + 23 more
- Conditions
- Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
- Interventions
- Bendamustine, Pralatrexate, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Echocardiography Test, Lumbar Puncture, Magnetic Resonance Imaging, Multigated Acquisition Scan, Peripheral Blood Stem Cell Transplantation, Positron Emission Tomography, Questionnaire Administration, Total-Body Irradiation, Biospecimen Collection
- Drug · Procedure · Other + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Interventions
- SARS-CoV-2 mRNA Vaccine ARCT-021, Tozinameran, Biospecimen Collection, Electronic Health Record Review, Survey Administration
- Biological · Procedure · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, pH Low Insertion Peptide-exatecan Conjugate CBX-12, X-Ray Imaging
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 15
- States / cities
- Irvine, California • Los Angeles, California • Orange, California + 11 more
- Conditions
- Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma, Duodenal Carcinoma, Familial Adenomatous Polyposis
- Interventions
- Biopsy Procedure, Biospecimen Collection, Gastrointestinal Endoscopy, Obeticholic Acid, Placebo Administration, Questionnaire Administration
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Kansas City, Kansas • Boston, Massachusetts + 3 more
- Conditions
- Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
- Interventions
- Avelumab, Axitinib, Biospecimen Collection, Bone Scan, Cabozantinib, Computed Tomography, Ipilimumab, Lenvatinib, Magnetic Resonance Imaging, Nivolumab, Pembrolizumab, Stereotactic Ablative Radiotherapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 342
- States / cities
- Birmingham, Alabama • Kingman, Arizona • Phoenix, Arizona + 260 more
- Conditions
- High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma, Resectable Osteosarcoma
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dinutuximab, Magnetic Resonance Imaging, Magrolimab, Resection
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 35 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • San Francisco, California + 6 more
- Conditions
- Non-Malignant Neoplasm
- Interventions
- Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide, Lapine T-Lymphocyte Immune Globulin, Total-Body Irradiation, Hematopoietic Cell Transplantation, Mycophenolate Mofetil, Sirolimus, Bone Marrow Aspiration, Biospecimen Collection
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor, Unresectable Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Pharmacodynamic Study, Positron Emission Tomography, Telaglenastat Hydrochloride
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 23 more
- Conditions
- Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
- Interventions
- Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Navitoclax, Positron Emission Tomography, Trametinib
- Procedure · Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Volunteers
- Interventions
- Not listed
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 8 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Carcinoma, Colorectal Carcinoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Scan, Computed Tomography, Immunotherapy, Magnetic Resonance Imaging, Positron Emission Tomography, Stereotactic Body Radiation Therapy
- Procedure · Drug · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Siltuximab
- Procedure · Biological
- Lead sponsor
- Timothy Voorhees
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Leptomeninges, Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Involved-Field Radiation Therapy, Lumbar Puncture, Magnetic Resonance Imaging, Positron Emission Tomography, Proton Beam Craniospinal Irradiation, Quality-of-Life Assessment
- Procedure · Radiation · Other
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 58
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Encinitas, California + 45 more
- Conditions
- Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, D Vitamin, Dual X-ray Absorptiometry, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Dietary Supplement · Drug + 1 more
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 50 Years and older · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 51
- States / cities
- Newark, Delaware • Danville, Illinois • Decatur, Illinois + 39 more
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Communication Intervention, Genetic Testing, Survey Administration
- Procedure · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Capivasertib, Cediranib Maleate, Computed Tomography, Durvalumab, Echocardiography Test, Multigated Acquisition Scan, Olaparib
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 760
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 481 more